Advancing Healthcare Innovation Through Strategic Capital Advisory
Cereona Partners is a senior strategic advisor to boards, shareholders, and management teams of growth-stage healthcare companies operating at the intersection of corporate strategy, corporate development, and capital markets.
Strategic Advisory Across the Capital Lifecycle
Strategic Advisory Across the Capital Lifecycle
Our Services
Our perspective extends beyond the deal to identify the right growth partners, align capital deployment with strategic priorities, and structure transactions to maximize value.
-
Advise on growth priorities, strategic alternatives, capital requirements, and use of proceeds
Support long-term enterprise value creation
-
Develop financing strategies
Identify aligned capital partners, and advise on valuation
Security structures, transaction terms, and execution
-
Evaluate and execute strategic partnerships, acquisitions, recapitalizations, and exits
Advance corporate objectives and accelerate value creation
-
Leverage proprietary market intelligence and relationships to originate opportunities
Identify counterparties, and facilitate strategically aligned transactions
From Strategic Insight to Transaction Execution
Diagnose — Assess the business, growth drivers, strategic priorities, and capital requirements through an institutional investor lens.
Architect — Develop the capital strategy, evaluate transaction alternatives, and advise on valuation, structure, proceeds allocation, and stakeholder alignment.
Position — Translate the company’s value proposition into a differentiated investment thesis that anticipates investor diligence and builds institutional conviction.
Curate — Identify and engage a targeted set of capital partners and strategic counterparties based on investment fit, strategic alignment, and probability of execution.
Execute — Maintain transaction momentum, navigate diligence, advise on commercial and economic terms, and coordinate stakeholders through closing.
Strategic alignment. Institutional credibility. Disciplined execution.
Diagnose
Assess the business, growth drivers, strategic priorities, and capital requirements through an institutional investor lens.
Architect
Develop the capital strategy, evaluate transaction alternatives, and advise on valuation, structure, proceeds allocation, and stakeholder alignment.
Position
Translate the company’s value proposition into a differentiated investment thesis that anticipates investor diligence and builds institutional conviction.
Curate
Identify and engage a targeted set of capital partners and strategic counterparties based on investment fit, strategic alignment, and probability of execution.
Execute
Maintain transaction momentum, navigate diligence, advise on commercial and economic terms, and coordinate stakeholders through closing.
Strategic alignment. Institutional credibility. Disciplined execution.
Client Results
Aligned Capital, Active in the Market
Cereona invests in the categories we advise, and we’ve invested in our clients, in every closed round.
Affect Therapeutics — Digital addiction treatment. Investor & Advisor · $26M Series B · Nov 2025
ChronicleBio — Multi-omic AI platform · chronic disease. Investor & Advisor · Growth Financing · Aug 2026
Curve Biosciences — Whole-body blood tests · chronic disease. Investor
Homethrive — Caregiver support & navigation. Investor · Diligence support to lead · $20M Series C · Nov 2024
Lilu — Maternal health devices. Investor · Acquired
Orchestra Oncology — Precision medicine workflow software. Investor
Tiny Health — Microbiome testing · mothers & infants. Investor
¹ Aggregate value of transactions and investments in which Cereona’s founder participated, principally in prior institutional roles (Novo Holdings, Leerink Partners) and as an independent advisor and investor. This figure is not Cereona Partners’ own transaction history.
Investments shown are personal holdings of Cereona’s founder and are not offered through Cereona Partners or Finalis Securities LLC. Selected holdings; not a complete list. Where Cereona Partners has also served as advisor, that engagement interest is disclosed in transaction materials. Securities offered through Finalis Securities LLC, member FINRA/SIPC.
About Cereona Partners
Cereona Partners provides strategic capital formation and advisory services for growth stage healthcare companies.
Every seat at the table
15+ years across principal investing, strategy, and operations, with credibility earned in operating roles alongside founders and management teams.
Relationships that open doors
Trusted relationships with top-tier institutions and investors, and an active presence in New York, Nashville, and San Francisco.
Senior, direct access
A discreet, direct-access model that avoids the adverse selection common in banker-led introductions. Lean, senior-led execution, with no insight lost to junior delegation.
Tech-enabled, personally delivered
AI-enabled workflows that sharpen analysis and speed, with hands-on attention throughout.
Our name combines Ceres—the Roman goddess of human flourishing—with corona, the sun’s halo revealed during an eclipse. The name reflects our mission: illuminate what others may not see and back transformative ideas that advance human flourishing and planetary health.
Team
We are partners who have sat in every seat: investor, operator, and board member.
Opal Joshi
Founder & CEO
Opal Joshi is the Founder and CEO of Cereona Partners. She is a healthcare industry insider who has built companies, underwritten risk, and executed complex transactions, giving her a full-stack view of how outcomes are actually created.
Cereona Partners is her answer to bring a new approach to dealmaking: tech-native, rigorously prepared, and designed for innovation.
Past Experience
Leerink Partners – Head of Middle Market Sponsor Coverage
Novo Holdings – Private equity, pharma services and healthcare technology
Formation Bio – In-licensing and business development
Flatiron Health – Strategic partnerships and JVs
Roivant Sciences – In-licensing and commercial development
Deloitte Consulting – Strategy & Operations, healthcare buy-side and sell-side
Advisor to Outcomes Collective Growth Capital
MBA, The Wharton School. BS in Actuarial Science and Finance, The Ohio State University. Holds Series 7 and 63.
Managing Director
Joining soon
Contact Us
Whether you are preparing for a raise, weighing strategic alternatives, or exploring a transaction, we welcome the conversation. Share a few details about your company and objectives, and Opal will follow up directly.